癌症（英文版）2016，Vol.35Issue(4)：171-180,10.DOI:10.1186/s40880-016-0086-2
Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
摘要
关键词
EGFR exon 19 deletion/EGFR exon 21 L858R point mutation/Lung adenocarcinoma/Treatment efcacyKey words
EGFR exon 19 deletion/EGFR exon 21 L858R point mutation/Lung adenocarcinoma/Treatment efcacy引用本文复制引用
Jiang-Yong Yu,Si-Fan Yu,Shu-Hang Wang,Hua Bai,Jun Zhao,Tong-Tong An,Jian-Chun Duan,Jie Wang..Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21[J].癌症（英文版）,2016,35(4):171-180,10.基金项目
We thank Dr. Ning Wang, a radiologist from Radiology Department of Beijing Cancer Hospital & Institute, for his contribution to response assessment （）
and Qianqian Song, from Novogene Company, for her contribution to biology information processing. This work was supported by grants from the National Natural Sciences Foundation Key Program (No.81330062), Education Ministry Innovative Research Team Program (No. IRT13003), Peking University-Tsinghua University Joint Center for Life Sciences Clinical Investigator, National High Technology Research and Development Program 863(No. SS2015AA020403), Beijing Technology Project (No. Z141100000214013) （No.81330062）
